What is The AACE Patient Safety Exchange?
Dr. Richard Hellman - AACE Immediate Past President
Skip Intro
Featured Case Study:
Seizures Following Therapy for Osteoporosis
A 60-year-old man was seen after presenting to the emergency room with seizures. His history is notable for having had gastric bypass surgery 5 years ago for obesity. About 2 months before, he injured himself playing tennis. An x-ray did not show a ...
[Read the Full Study]
Submitted by:
Dr. Steven Petak
Featured Case Study:
Post Operative Hypernatremia: A Simple but Dangerous Oversight
The patient is a 63-year-old Caucasian female with a history of central diabetes insipidus following resection of a nonfunctioning pituitary macroadenoma. The patient had been stable with normal electrolyte and fluid balance taking desmopressin 0.2 mg orally twice a day. ...
[Read the Full Study]
Submitted by:
Dr. Fred A. Williams, Jr.
What's New
Is there a link between Lantus (insulin glargine) and cancer? A commentary on reports from the FDA and the EASD on the possible association.

 

Patient Safety Issues in the U.S – The dangers of an overly narrow focus

 

Insulin Pens and Safety – a suggestion from Dr. Irl Hirsch

 

Patient Safety and Bilingualism

 

Patient Safety, Insulin Pumps, and Cognitive Dysfunction

 

The FDA Med-Watch Alert on Stolen Levemir – Is this just one example of a much bigger patient safety problem?

 

New editorial by Dr David Cooper in Response to the FDA Safety Alert on Propylthiouracil

 

Leer nuevos español traducido editoriales
Current News

FDA Alert RE: Levemir

The U.S. Food and Drug Administration has learned that some stolen vials of the long-acting insulin Levemir made by Novo Nordisk Inc. have reappeared and are being sold in the U.S. market. Three lots or a total of 129,000 vials of this product were stolen in all. These stolen insulin vials may not have been stored and handled properly and may be dangerous for patients to use.

[Read More]

FDA Imposes Restrictions on Coast IRB due to Violations

The U.S Food and Drug Administration today announced that Coast IRB, LLC of Colorado Springs, Colo., has agreed to voluntarily halt some aspects of its clinical trial oversight operations due to serious concerns about the company's ability to protect human subjects participating in clinical trials.

[Read More]

FINAL RULE ISSUED FOR PATIENT SAFETY ORGANIZATIONS

The U.S. Department of Health and Human Services has issued a final rule for Patient Safety Organizations (PSOs).

[Read More]

7.15.08
Patient Safety: The Joint Commission Perspective
Submitted by:
Peter B. Angood MD, FRCS(C), FACS, FCCM
[View]
5.20.08
NQF National Priorities Partnership: Leveraging Our Collective Efforts to Improve Safety & Quality
Submitted by:
Janet M. Corrigan, PhD, MBA
[View]
Disclaimer:
This site is for informational purposes only. For issues of an individual clinical nature please consult your physician, as medical advice will not be provided through this site. Articles and opinions expressed on the exchange do not necessarily represent the policies and/or opinions of the American Association of Clinical Endocrinologists.

 

American Association of Clinical Endocrinologists
245 Riverside Avenue Suite 200
Jacksonville, FL 32202
904.353.7878